Danaher is trading 4.46% up at $208.49, recovering from the August 18 close of $199.58 as healthcare gains followed positive late-stage melanoma vaccine results.
- No company-specific announcement or analyst action was identified for August 19, 2026.
- Healthcare is up 1.90% after Merck and Moderna’s results met primary and secondary goals, Reuters reported, lifting biotechnology sentiment.
- Broader indexes are modestly higher, but sector strength appears more relevant.